Kenneth Lim1, Stephen M S Ting2, Thomas Hamborg3, Gordon McGregor4,5, David Oxborough6, Claudia Tomkins7, Dihua Xu1, Ravi Thadhani1, Gregory Lewis8, Rosemary Bland9, Prithwish Banerjee5,10, Simon Fletcher4, Nithya S Krishnan4, Robert Higgins4, Daniel Zehnder11,12, Thomas F Hiemstra13. 1. Division of Nephrology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston. 2. Department of Medicine, University Hospitals Birmingham National Health Service Foundation Trust, Birmingham, United Kingdom. 3. Pragmatic Clinical Trials Unit, Centre for Primary Care and Public Health, Queen Mary, University of London, London, United Kingdom. 4. Department of Nephrology, University Hospital Coventry and Warwickshire National Health Service Trust, Coventry, United Kingdom. 5. Department of Cardiology, University Hospital Coventry and Warwickshire National Health Service Trust, Coventry, United Kingdom. 6. Research Institutes of Sports and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom. 7. Department of Pathology Service, University Hospital Coventry and Warwickshire National Health Service Trust, Coventry, United Kingdom. 8. Division of Cardiology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston. 9. Division of Biomedical Sciences, University of Warwick, Coventry, United Kingdom. 10. Centre for Innovative Research Across the Life Course, Coventry University, Coventry, United Kingdom. 11. Department of Nephrology, North Cumbria University Hospital National Health Service Trust, Carlisle, United Kingdom. 12. Department of Acute Medicine, North Cumbria University Hospital National Health Service Trust, Carlisle, United Kingdom. 13. Cambridge Clinical Trials Unit and School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom.
Abstract
Importance: Restitution of kidney function by transplant confers a survival benefit in patients with end-stage renal disease. Investigations of mechanisms involved in improved cardiovascular survival have relied heavily on static measures from echocardiography or cardiac magnetic resonance imaging and have provided conflicting results to date. Objectives: To evaluate cardiovascular functional reserve in patients with end-stage renal disease before and after kidney transplant and to assess functional and morphologic alterations of structural-functional dynamics in this population. Design, Setting, and Participants: This prospective, nonrandomized, single-center, 3-arm, controlled cohort study, the Cardiopulmonary Exercise Testing in Renal Failure and After Kidney Transplantation (CAPER) study, included patients with stage 5 chronic kidney disease (CKD) who underwent kidney transplant (KTR group), patients with stage 5 CKD who were wait-listed and had not undergone transplant (NTWC group), and patients with hypertension only (HTC group) seen at a single center from April 1, 2010, to January 1, 2013. Patients were followed up longitudinally for up to 1 year after kidney transplant. Clinical data collection was completed February 2014. Data analysis was performed from June 1, 2014, to March 5, 2015. Further analysis on baseline and prospective data was performed from June 1, 2017, to July 31, 2019. Main Outcomes and Measures: Cardiovascular functional reserve was objectively quantified using state-of-the-art cardiopulmonary exercise testing in parallel with transthoracic echocardiography. Results: Of the 253 study participants (mean [SD] age, 48.5 [12.7] years; 141 [55.7%] male), 81 were in the KTR group, 85 in the NTWC group, and 87 in the HTC group. At baseline, mean (SD) maximum oxygen consumption (V̇O2max) was significantly lower in the CKD groups (KTR, 20.7 [5.8] mL · min-1 · kg-1; NTWC, 18.9 [4.7] mL · min-1 · kg-1) compared with the HTC group (24.9 [7.1] mL · min-1 · kg-1) (P < .001). Mean (SD) cardiac left ventricular mass index was higher in patients with CKD (KTR group, 104.9 [36.1] g/m2; NTWC group, 113.8 [37.7] g/m2) compared with the HTC group (87.8 [16.9] g/m2), (P < .001). Mean (SD) left ventricular ejection fraction was significantly lower in the patients with CKD (KTR group, 60.1% [8.6%]; NTWC group, 61.4% [8.9%]) compared with the HTC group (66.1% [5.9%]) (P < .001). Kidney transplant was associated with a significant improvement in V̇O2max in the KTR group at 12 months (22.5 [6.3] mL · min-1 · kg-1; P < .001), but the value did not reach the V̇O2max in the HTC group (26.0 [7.1] mL · min-1 · kg-1) at 12 months. V̇O2max decreased in the NTWC group at 12 months compared with baseline (17.7 [4.1] mL · min-1 · kg-1, P < .001). Compared with the KTR group (63.2% [6.8%], P = .02) or the NTWC group (59.3% [7.6%], P = .003) at baseline, transplant was significantly associated with improved left ventricular ejection fraction at 12 months but not with left ventricular mass index. Conclusions and Relevance: The findings suggest that kidney transplant is associated with improved cardiovascular functional reserve after 1 year. In addition, cardiopulmonary exercise testing was sensitive enough to detect a decline in cardiovascular functional reserve in wait-listed patients with CKD. Improved V̇O2max may in part be independent from structural alterations of the heart and depend more on ultrastructural changes after reversal of uremia.
Importance: Restitution of kidney function by transplant confers a survival benefit in patients with end-stage renal disease. Investigations of mechanisms involved in improved cardiovascular survival have relied heavily on static measures from echocardiography or cardiac magnetic resonance imaging and have provided conflicting results to date. Objectives: To evaluate cardiovascular functional reserve in patients with end-stage renal disease before and after kidney transplant and to assess functional and morphologic alterations of structural-functional dynamics in this population. Design, Setting, and Participants: This prospective, nonrandomized, single-center, 3-arm, controlled cohort study, the Cardiopulmonary Exercise Testing in Renal Failure and After Kidney Transplantation (CAPER) study, included patients with stage 5 chronic kidney disease (CKD) who underwent kidney transplant (KTR group), patients with stage 5 CKD who were wait-listed and had not undergone transplant (NTWC group), and patients with hypertension only (HTC group) seen at a single center from April 1, 2010, to January 1, 2013. Patients were followed up longitudinally for up to 1 year after kidney transplant. Clinical data collection was completed February 2014. Data analysis was performed from June 1, 2014, to March 5, 2015. Further analysis on baseline and prospective data was performed from June 1, 2017, to July 31, 2019. Main Outcomes and Measures: Cardiovascular functional reserve was objectively quantified using state-of-the-art cardiopulmonary exercise testing in parallel with transthoracic echocardiography. Results: Of the 253 study participants (mean [SD] age, 48.5 [12.7] years; 141 [55.7%] male), 81 were in the KTR group, 85 in the NTWC group, and 87 in the HTC group. At baseline, mean (SD) maximum oxygen consumption (V̇O2max) was significantly lower in the CKD groups (KTR, 20.7 [5.8] mL · min-1 · kg-1; NTWC, 18.9 [4.7] mL · min-1 · kg-1) compared with the HTC group (24.9 [7.1] mL · min-1 · kg-1) (P < .001). Mean (SD) cardiac left ventricular mass index was higher in patients with CKD (KTR group, 104.9 [36.1] g/m2; NTWC group, 113.8 [37.7] g/m2) compared with the HTC group (87.8 [16.9] g/m2), (P < .001). Mean (SD) left ventricular ejection fraction was significantly lower in the patients with CKD (KTR group, 60.1% [8.6%]; NTWC group, 61.4% [8.9%]) compared with the HTC group (66.1% [5.9%]) (P < .001). Kidney transplant was associated with a significant improvement in V̇O2max in the KTR group at 12 months (22.5 [6.3] mL · min-1 · kg-1; P < .001), but the value did not reach the V̇O2max in the HTC group (26.0 [7.1] mL · min-1 · kg-1) at 12 months. V̇O2max decreased in the NTWC group at 12 months compared with baseline (17.7 [4.1] mL · min-1 · kg-1, P < .001). Compared with the KTR group (63.2% [6.8%], P = .02) or the NTWC group (59.3% [7.6%], P = .003) at baseline, transplant was significantly associated with improved left ventricular ejection fraction at 12 months but not with left ventricular mass index. Conclusions and Relevance: The findings suggest that kidney transplant is associated with improved cardiovascular functional reserve after 1 year. In addition, cardiopulmonary exercise testing was sensitive enough to detect a decline in cardiovascular functional reserve in wait-listed patients with CKD. Improved V̇O2max may in part be independent from structural alterations of the heart and depend more on ultrastructural changes after reversal of uremia.
Authors: Stephen M S Ting; Hasan Iqbal; Hemali Kanji; Thomas Hamborg; Nicolas Aldridge; Nithya Krishnan; Chris H E Imray; Prithwish Banerjee; Rosemary Bland; Robert Higgins; Daniel Zehnder Journal: J Am Soc Nephrol Date: 2013-11-14 Impact factor: 10.121
Authors: Stephen M S Ting; Thomas Hamborg; Gordon McGregor; David Oxborough; Kenneth Lim; Sudheer Koganti; Nicolas Aldridge; Chris Imray; Rosemary Bland; Simon Fletcher; Nithya S Krishnan; Robert M Higgins; Jonathan Townend; Prithwish Banerjee; Daniel Zehnder Journal: Am J Kidney Dis Date: 2015-04-18 Impact factor: 8.860
Authors: D Montanaro; M Gropuzzo; P Tulissi; C Vallone; G Boscutti; R Mioni; A Risaliti; U Baccarani; G L Adani; M Sainz; D Lorenzin; F Bresadola; G Mioni Journal: Transplant Proc Date: 2005 Jul-Aug Impact factor: 1.066
Authors: R K Patel; P B Mark; N Johnston; R McGeoch; M Lindsay; D B Kingsmore; H J Dargie; A G Jardine Journal: Am J Transplant Date: 2008-05-28 Impact factor: 8.086
Authors: Herwig-Ulf Meier-Kriesche; Jesse D Schold; Titte R Srinivas; Alan Reed; Bruce Kaplan Journal: Am J Transplant Date: 2004-10 Impact factor: 8.086
Authors: Rajan K Patel; Patrick B Mark; Nicola Johnston; Ellon McGregor; Henry J Dargie; Alan G Jardine Journal: Clin J Am Soc Nephrol Date: 2008-07-23 Impact factor: 8.237
Authors: Felix Hohendanner; Senka Ljubojević; Niall MacQuaide; Michael Sacherer; Simon Sedej; Liesbeth Biesmans; Paulina Wakula; Dieter Platzer; Sophie Sokolow; André Herchuelz; Gudrun Antoons; Karin Sipido; Burkert Pieske; Frank R Heinzel Journal: Circ Res Date: 2013-07-03 Impact factor: 17.367
Authors: Sangita Choudhury; Soochan Bae; Qingen Ke; Ji Yoo Lee; Sylvia S Singh; René St-Arnaud; Federica Del Monte; Peter M Kang Journal: PLoS One Date: 2014-09-30 Impact factor: 3.240
Authors: Nicola C Edwards; William E Moody; Colin D Chue; Charles J Ferro; Jonathan N Townend; Richard P Steeds Journal: JACC Cardiovasc Imaging Date: 2014-07
Authors: Stephen M S Ting; Hasan Iqbal; Thomas Hamborg; Chris H E Imray; Susan Hewins; Prithwish Banerjee; Rosemary Bland; Robert Higgins; Daniel Zehnder Journal: PLoS One Date: 2013-05-27 Impact factor: 3.240
Authors: Arvin Halim; Heather N Burney; Xiaochun Li; Yang Li; Claudia Tomkins; Andrew M Siedlecki; Tzong-Shi Lu; Sahir Kalim; Ravi Thadhani; Sharon Moe; Stephen M S Ting; Daniel Zehnder; Thomas F Hiemstra; Kenneth Lim Journal: Kidney360 Date: 2022-07-05